Dr Sarah Lynagh joined Fios Genomics in April 2012 and has over 10 years’ experience in drug development and commercialization predominantly within contract research organizations. Sarah was a Research Fellow at Cancer Research UK specializing in the development of novel treatments for colon and ovarian cancers. She then left academia to begin her industry career as a Study Director for Quintiles (Edinburgh) which lead to a move to Singapore to establish Maccine, preclinical CRO specializing in translational models of preclinical safety and efficacy.

After 3 years in Asia, she returned to the UK to join BTG heading up the Preclinical Drug Development team and later Biopta Ltd in the position of Head of Research & Development.

Sarah has a degree in Pharmacology and a PhD in Neuropharmacology both from the University of Glasgow and is a member of the Industrial Advisory Board in the Department of Informatics at King’s College, London. She is also a Board Observer representing SMEs within the Stratified Medicine Scotland Innovation Centre.